Pleno, Inc. is a clinical and multi-omics diagnostics company focused on revolutionizing biological target detection with its RAPTOR™ multi-omic instrument platform.

GC Therapeutics (GCTx) develops off-the-shelf iPSC-based cell therapy products for gastrointestinal, neurological, and immunological diseases using their innovative TFome platform.

ProJenX is a biotechnology company developing a lead compound, prosetin, for the treatment of ALS and other brain diseases, with funding from a $15 million Series A financing round led by Medical Excellence Capital and collaboration with Project ALS and Columbia University.